Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer-Reference-Cited by-同舟云学术

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer

Published:2019-03-11 Issue:4 Volume:10 Page:1005-1008
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Mouri Atsuto¹,Kaira Kyoichi¹^ORCID,Shiono Ayako¹,Yamaguchi Ou¹,Murayama Yoshitake¹,Kobayashi Kunihiko¹,Kagamu Hiroshi¹

Affiliation:

1. Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical CenterSaitama University Hospital Hidaka Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13022

Reference7 articles.

1. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

2. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

3. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline

4. Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer

5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Filgrastim Used for Infection Prophylaxis for Moderate Neutropenia Related to Primary Myelodysplasia Prior to Elective Surgery: A Case Report;EMJ Hematology;2024-07-25

2. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051;Scientific Reports;2024-02-15

3. Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022;International Journal of Clinical Oncology;2024-02-14

4. Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment;Thoracic Cancer;2023-11-14

5. Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment;Scientific Reports;2023-11-09